Medicaid Coverage Policy for Perjeta (pertuzumab) Injection
Customize your policy alerts
Sign up for all cdphp policy alerts
Know when cdphp releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs Medicaid coverage of Perjeta (pertuzumab) injection for specified HER2-positive breast cancer indications, including metastatic, neoadjuvant, and adjuvant treatment.
No material clinical or coverage changes in this revision.
Covered Indications
Covered Indications
Perjeta is covered when the patient meets ANY ONE of the following listed indications:
Listed indications
- Metastatic breast cancer: HER2-positive metastatic breast cancer treated in combination with trastuzumab and docetaxel in a patient who has not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
- Neoadjuvant breast cancer: HER2-positive, locally advanced, inflammatory, or early-stage breast cancer treated neoadjuvantly in combination with trastuzumab and chemotherapy, with early-stage disease greater than 2 cm in diameter or node positive, as part of a complete treatment regimen for early breast cancer.> 2 cm in diameter or node positive
- Adjuvant breast cancer:
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.